title: Gleason grading controversies: what the chemoprevention trials have taught us.
abstract: The recent Prostate Chemoprevention Trial (PCPT), which assessed the efficacy of finasteride in reducing prostate cancer incidence, showed promising results. However, patients who developed cancer had higher Gleason scores than those on placebo. Moreover, recent evidence has shown that the biopsy Gleason scores in patients on finasteride were actually more accurate compared with patients on placebo when matched with the final, radical prostatectomy (RP) scores. This accuracy was due to a reduction in prostate volume induced by the drug, and better performance of prostate-specific antigen correlation for identifying men with high-grade cancer. Re-evaluation of the results based on the pathology of the RP specimens and longer follow-up showed a 30% reduction in cancer incidence with finasteride and no significant differences in Gleason scores compared with placebo.
authors: Professor, Department of Surgery, University of Toronto, Toronto, ON;
authors: Laurence
authors: L
authors: Klotz
authors: Darrel
authors: D
authors: Drachenberg
authors: Yves
authors: Y
authors: Fradet
authors: Fred
authors: F
authors: Saad
authors: John
authors: J
authors: Trachtenberg
authors: Alexandre
authors: A
authors: Zlotta